Magnesium monitoring practice in monoclonal anti-epidermal growth factor receptor antibodies therapy.

@article{PazoOubia2013MagnesiumMP,
  title={Magnesium monitoring practice in monoclonal anti-epidermal growth factor receptor antibodies therapy.},
  author={F do Pazo-Oubi{\~n}a and Anna Estefanell-Tejero and Gisela Riu-Viladoms and Helena Anglada-Mart{\'i}nez and Gl{\`o}ria Molas-Ferrer and Nat{\`a}lia Creus-Bar{\'o}},
  journal={Journal of clinical pharmacy and therapeutics},
  year={2013},
  volume={38 2},
  pages={101-3}
}
WHAT IS KNOWN AND OBJECTIVE It is now estimated that about 5% of cetuximab-treated patients and about 3% of panitumumab-treated patients will develop grade 3-4 hypomagnesemia. The aim of this study was to assess the extent of magnesium monitoring in patients treated with epidermal growth factor receptor (EGFR)-targeting antibodies and to estimate the incidence of hypomagnesemia in these patients at our institution. METHODS A 2-year retrospective study was carried out. At least four doses of… CONTINUE READING